Editas Medicine announced on October 22, 2024, the achievement of in vivo preclinical proof of concept for HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs). This was accomplished using the Company’s proprietary targeted lipid nanoparticle (tLNP) delivery system.
This preclinical milestone represents a key step forward in developing a novel in vivo treatment for sickle cell disease and beta thalassemia. The Company also initiated a process to partner or out-license its ex vivo reni-cel program.
The decision to seek a partner for reni-cel is intended to focus Editas Medicine's resources on its in vivo pipeline development. This strategic update highlights the Company's commitment to advancing its in vivo gene editing capabilities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.